CytoDyn Inc.

CYDY ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Assets
Cash & Equivalents $11.9M $11.9M $3.1M $2.5M $4.2M $33.9M $14.3M $2.6M
Accounts Receivable — — — — — — — —
Inventory — — $0 $0 — $93.5M $19.1M —
Total Current Assets $13.9M $17.9M $10.8M $10.8M $10.5M $36.1M $36.8M $5.4M
Property, Plant & Equipment — — — — $73.0K $134.0K $55.0K $29.3K
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) — — — — $132.0K $1.7M $13.5M $15.5M
Total Assets $14.0M $18.0M $11.1M $11.3M $29.2M $132.1M $50.5M $20.9M
Liabilities
Accounts Payable $13.2M $14.7M $29.6M $62.7M $68.0M $65.9M $29.5M $16.2M
Total Current Liabilities $53.7M $70.5M $84.2M $119.8M $123.2M $152.5M $44.5M $26.9M
Long-Term Debt $38.3M $45.4M $45.0M $45.7M $42.2M $64.8M — —
Total Liabilities $123.7M $114.1M $127.9M $120.8M $123.6M $153.1M $53.0M $29.8M
Stockholders' Equity
Retained Earnings $-930.5M $-887.8M $-891.5M $-841.7M $-766.1M $-639.9M $-445.2M $-229.4M
Total Stockholders' Equity $-109.7M $-96.0M $-116.8M $-109.5M $-94.4M $-21.0M $-2.5M $-8.9M
← Newer Page 1 of 2 Older →